Uniqure B.V. News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.08.18	uniQure to Participate at Multiple Upcoming Conferences (GlobeNewswire)
23.08.18	uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B (GlobeNewswire)
08.08.18	uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress (GlobeNewswire)
29.06.18	QURE Exudes Hope, ZFGN Catches Eyes, NDRA On Watch, XENE Hits New High (RTTNews)
28.06.18	uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B (GlobeNewswire)
13.06.18	uniQure Announces New Appointments to its Board of Directors (GlobeNewswire)
29.05.18	uniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene Therapy (GlobeNewswire)
21.05.18	uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies (GlobeNewswire)
18.05.18	uniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene Therapy (GlobeNewswire)
07.05.18	uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares (GlobeNewswire)
03.05.18	uniQure Announces Pricing of its Public Offering (GlobeNewswire)
01.05.18	uniQure Announces Proposed Public Offering (GlobeNewswire)
30.04.18	uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
30.04.18	uniQure Announces First Quarter 2018 Financial Results and Highlights Company Progress (GlobeNewswire)
27.04.18	uniQure Announces to Present at Multiple Conferences in May (GlobeNewswire)
25.04.18	uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington's Disease at the 2018 American Academy of Neurology Annual Meeting (GlobeNewswire)
10.04.18	RGNX On Watch, BOLD To Report Data In Q2, ONCE Sparkles, So Long To AVXS (RTTNews)
14.03.18	uniQure Announces 2017 Financial Results and Recent Company Progress (GlobeNewswire)
27.02.18	uniQure to Participate in Multiple Conferences in March (GlobeNewswire)
13.02.18	DARE Emboldened, IFRX On Track, APRI Awaits FDA Word, Watch Out For DYNT (RTTNews)
01.02.18	uniQure to Participate in Multiple Conferences in February (GlobeNewswire)
22.01.18	uniQure Receives Orphan Medicinal Product Designation in Europe for AMT-130 in Huntington's disease (GlobeNewswire)
08.01.18	uniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value (GlobeNewswire)
18.12.17	uniQure Announces Publication in the Journal Blood of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B (GlobeNewswire)
11.12.17	uniQure Added to NASDAQ Biotechnology Index (GlobeNewswire)
11.12.17	uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B (GlobeNewswire)
09.12.17	uniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
01.11.17	uniQure Announces Presentations at the 59th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
01.11.17	uniQure Announces Third Quarter 2017 Financial Results and Recent Company Progress (GlobeNewswire)
31.10.17	uniQure Announces Multiple Company Presentations at Upcoming November Conferences (GlobeNewswire)
27.10.17	uniQure Announces Closing of its Public Offering (GlobeNewswire)
26.10.17	MGNX Soars On INCY Deal, CDTX Strides Ahead, NUVA Entices, ACHC In Poor Health (RTTNews)
25.10.17	uniQure Announces Pricing of its Public Offering (GlobeNewswire)
24.10.17	FDA Approves New Use For Soliris, HSTM In Good Health, BYSI Springs A Surprise (RTTNews)
23.10.17	uniQure Announces Proposed Public Offering (GlobeNewswire)
20.10.17	In The Spotlight: UniQure (RTTNews)
20.10.17	QURE On Fast Track, Music To CNCE's Ears, CRBP Gets A Facelift, OBLN Deflated (RTTNews)
19.10.17	uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX (FIX-Padua) (GlobeNewswire)
19.10.17	uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018 (GlobeNewswire)
19.10.17	SPPI Breathes Easy On Trial Results, PTI Awaits Data In Q4, HAIR Keeps Receding (RTTNews)
18.10.17	uniQure Presents New Preclinical Data on AMT-130 in Huntington's Disease at the ESGCT 25th Anniversary Congress in Berlin (GlobeNewswire)
17.10.17	HIIQ In Good Health, BOLD Awaits ASPIRO Data, CELESTIAL Lights Up EXEL (RTTNews)
06.10.17	uniQure Announces FDA Orphan Drug Designation for AMT-130 in Huntington's disease (GlobeNewswire)
02.10.17	uniQure Announces Company Presentations at Upcoming October Conferences (GlobeNewswire)
22.09.17	IPXL Mulls Merger, QURE Attracts Attention, No Let Up In ICPT Ocaliva Concerns (RTTNews)
30.08.17	ACHV Focuses On Achievement, IMGN Strikes Chord With JAZZ, FDA Snubs ACOR (RTTNews)
24.08.17	uniQure Announces Company Participation at Citi Healthcare Conference (GlobeNewswire)
08.08.17	uniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress (GlobeNewswire)
07.08.17	uniQure Announces Leadership Team Appointments and Nominations to its Board of Directors (GlobeNewswire)
31.07.17	uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Uniqure B.V.

Aktien Top/Flop

Meistgelesene Nachrichten